RWM
VRTX icon

Rialto Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Rialto Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.8K Buy
199
+113
+131% +$50.1K 0.02% 249
2026
Q1 		$38.4K Buy
86
+83
+2,767% +$38.7K 0.01% 309
2025
Q4 		$1.36K Buy
3
+2
+200% +$862 ﹤0.01% 895
2025
Q3 		$392 Hold
1
– – ﹤0.01% 1330
2025
Q2 		$446 Sell
1
-3
-75% -$1.38K ﹤0.01% 1208
2025
Q1 		$1.94K Buy
+4
New +$1.86K ﹤0.01% 539

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Rialto Wealth Management's VRTX Position: Q2 2026 in Review

Rialto Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 131% in Q2 2026, buying an estimated $50.1K and bringing the position to 199 shares worth $98.8K. The position accounts for 0.02% of the portfolio, ranked #249.

Rialto Wealth Management first reported a position in VRTX in Q1 2025 and has held it in 6 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Rialto Wealth Management held 199 shares of Vertex Pharmaceuticals worth $98.8K as of Q2 2026.
  • Rialto Wealth Management bought 113 Vertex Pharmaceuticals shares in Q2 2026, an estimated $50.1K.
  • Vertex Pharmaceuticals made up 0.02% of Rialto Wealth Management's portfolio in Q2 2026, its #249 holding.
  • Rialto Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.